

This is the peer reviewed version of the following article:

Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden / Boriani, Giuseppe; Glotzer, Taya V.; Ziegler, Paul D.; De Melis, Mirko; Mangoni di S. Stefano, Lorenza; Sepsi, Milan; Landolina, Maurizio; Lunati, Maurizio; Lewalter, Thorsten; Camm, A. John. - In: HEART RHYTHM. - ISSN 1547-5271. - 15:3(2018), pp. 376-383. [10.1016/j.hrthm.2017.11.007]

*Terms of use:*

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

20/01/2025 00:50

(Article begins on next page)

# Accepted Manuscript

Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden

Giuseppe Boriani, MD, Ph.D, Taya V. Glotzer, MD, Paul D. Ziegler, MSc, Mirko De Melis, Ph.D, Lorenza Mangoni di S. Stefano, MS, Milan Sepsi, MD, Ph.D, Maurizio Landolina, MD, Maurizio Lunati, MD, Thorsten Lewalter, MD, A. John Camm, MD

PII: S1547-5271(17)31321-8

DOI: [10.1016/j.hrthm.2017.11.007](https://doi.org/10.1016/j.hrthm.2017.11.007)

Reference: HRTM 7382

To appear in: *Heart Rhythm*

Received Date: 23 August 2017

Please cite this article as: Boriani G, Glotzer TV, Ziegler PD, De Melis M, Mangoni di S. Stefano L, Sepsi M, Landolina M, Lunati M, Lewalter T, Camm AJ, Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden, *Heart Rhythm* (2017), doi: 10.1016/j.hrthm.2017.11.007.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



# Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden

Revision of JHRM-D-17-01192R2

Giuseppe Boriani, MD, Ph.D\*, Taya V. Glotzer, MD†, Paul D. Ziegler§, MSc, Mirko De Melis, Ph.D§§, Lorenza Mangoni di S. Stefano, MS §§§, Milan Sepsi, MD, Ph.D¶, Maurizio Landolina, MD‡, Maurizio Lunati, MD\*\*, Thorsten Lewalter, MD¶¶, A. John Camm, MD#.

\*Cardiology Division. Department of Diagnostics, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy;

†Hackensack University Medical Center, Hackensack, NJ USA;

‡ Ospedale Maggiore, Crema (Cremona), Italy;

\*\*Niguarda Ca' Granda Hospital, Milano, Italy;

§Medtronic Inc., Minneapolis, Minnesota §§Medtronic Bakken Research Center, Maastricht, The Netherlands;

§§§Medtronic EMEA Regional Clinical Center, Rome, Italy,

¶Department of Internal Medicine – Cardiology, University Hospital Brno, Brno, Czech Republic;

¶¶Isar Heart Center Munich, Munich, Germany;

#Molecular and Clinical Sciences Research Institute, St. George's University of London, London, UK.

Short title: Atrial fibrillation burden in CIEDs

Word count (total): 4923

Correspondence to:

Prof. Giuseppe Boriani, MD, PhD, FESC, FEHRA.

Cardiology Division, Department of Diagnostics, Clinical and Public Health Medicine

University of Modena and Reggio Emilia, Policlinico di Modena

Via del Pozzo, 71, 41124 Modena, Italy

Phone +39-059-4225836

Fax: +39-059-4224498

E-mail: giuseppe.boriani@unimore.it

**Conflict of interest disclosure** G.B reported speaker's fees of small amount from Boehringer, Boston, Biotronik and Medtronic. T.V.G. has consulting (small amount): Medtronic and St Jude; Speakers bureau (small) : Medtronic, Inc., St Jude, and Boston Scientific. M.G.: Advisory Board Medtronic and Boston Scientific. M.S. receives research grant support from Medtronic, St Jude Medical, and Biotronik and honoraria from Medtronic and Bayer; has a speakers' bureau appointment with MSD, Medtronic, St Jude Medical, and AstraZeneca; and has an advisory board relationship with Boehringer Ingelheim. T.L. has received lecture fees Medtronic, Sanofi, Merck, Sharp & Dohme, Boehringer Ingelheim, Bayer, and Bristol-Myers Squibb. M.S. has no conflict of interest. J.A.C. serves as advisor and speaker for Astra Zeneca, ChanRX, Gilead, Merck, Menarini, Otsuka, Sanofi, Servier, Xention, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi, Pfizer, Boston Scientific, Biotronik, Medtronic, St Jude Medical, Actelion, GlaxoSmithKline, InfoBionic, Incarda, Johnson and Johnson, Mitsubishi, Novartis, Takeda. P.D.Z., M.D.M and L.M.S.S are employees of Medtronic.

**Abstract**

**Background:** *In patients with cardiac implanted electronic devices (CIEDs) detection of new atrial fibrillation (AF) is associated with an increased risk of stroke.*

**Objective:** *To characterize daily AF burden at first detection and the rate of temporal transition to higher device detected AF burden.*

**Methods:** *A pooled analysis of data from three prospective studies was analyzed and 6580 patients (mean age  $68\pm 12$  years, 72% male) with no history of AF and no anticoagulants at baseline were identified. Various thresholds of daily AF burden (5 minutes, 1, 6, 12 and 23 hours) were analyzed.*

**Results:** *Among the study population of 6580 patients, a new AF, with a AF burden of at least 5 min, was detected in 2244 patients (34%) during a follow up of  $2.4\pm 1.7$  years. Among these patients 1091 (49.8%) transitioned to a higher AF burden threshold during follow-up. A higher duration of daily AF burden manifest at first detection, as well as CHADS<sub>2</sub> score  $\geq 2$ , were associated with faster transition to a subsequent higher burden. Approximately 24% of patients transitioned from a lower threshold to a daily AF burden  $\geq 23$  hours during follow-up.*

**Conclusion:** *More than one third of patients with no history of AF develop device-detected AF, with attainment of different thresholds of daily AF burden over time. Continuous long-term monitoring, especially when the initial detection corresponds to a higher daily AF burden and the CHADS<sub>2</sub> score is 2 or more, could support timely clinical decisions on anticoagulation by capturing transitions to higher AF burden thresholds.*

**Key words:** *anticoagulants, atrial fibrillation; atrial fibrillation burden; cardioverter-defibrillator; pacemaker; stroke.*

## **Introduction**

The extensive monitoring capabilities of cardiac implanted electrical devices (CIEDs) with sensing of atrial activity currently allow the detection of episodes of atrial high rate events (AHRE) episodes also known as subclinical atrial fibrillation (SCAF)<sup>1-3</sup>. The relationship between the duration of AHREs and the risk of stroke is complex and is an area of active investigation<sup>4-6</sup>. Device-detected AF is associated with an increased risk of stroke,<sup>1,3,7,8</sup> but the precise threshold of device-detected AF that may justify initiation of oral anticoagulation (OAC) in patients with a clinical profile at risk, is not yet understood.<sup>3,9</sup>

Current guidelines recommend risk-based prescription of OAC in patients with clinically documented AF.<sup>10</sup> However, the guidelines do not account for AF burden, i.e., the length and frequency of AF episodes which vary greatly across and within patients. Further, many episodes of AF are clinically 'silent'. In patients with CIEDs, episodes of AHRE may occur, with a duration of minutes to hours leading to the concept of "subclinical AF".<sup>1-3</sup> In patients with CIED and no history of AF, detection of new AF is of potential importance and requires appropriate clinical management and decision making. Several different thresholds of daily AF burden (for example, 5-6 minutes, 1, 6, 12 and 23 hours) have been investigated in patients with CIEDs and an association with an increased risk of stroke has been demonstrated.<sup>11,12</sup> No controlled study has defined the specific threshold of AF burden that justifies initiation of OAC in patients at risk.

A comprehensive, accurate definition of the dynamics of device-detected AF, and of the factors influencing the transition from shorter to longer maximum daily AF burden could be helpful in clinical decision-making with regard to patient monitoring and surveillance, as well as for prescription of OAC. In this regard it is noteworthy that subclinical AF predicts the occurrence of clinical AF, as well as the risk of ischemic stroke/systemic embolism<sup>1,3</sup> but no data are currently available on the transition from a lower to a higher AF burden of device detected AHREs. The importance of investigating the transition to AF of long duration (longer than 23-24 hours) is stressed by a recent analysis from ASSERT showing that patients in whom

the longest episode of silent AF exceeded 24 hours had a significantly increased risk of stroke during follow up<sup>15</sup>.

The aim of the current work is to characterize the daily AF burden at first detection and the rate of temporal transition to a higher device detected AF burden from a large dataset that quantified the incidence of device-detected AF during follow up.

## **Methods**

A pooled analysis of individual patient data from three prospective studies (TRENDS, Italian Clinical Service, and PANORAMA), part of the SOS AF project,<sup>8</sup> was performed. The details of the methods are in the Supplementary web-only Appendix.

## **Results**

### **Patient characteristics and occurrence of device detected AF burden during follow up**

A group of 6580 patients implanted with a CIED (mean age  $67\pm 12$  years, 69% male) without history of AF and no OAC use at baseline were identified and followed for  $2.4\pm 1.7$  years. The clinical characteristics of these patients are shown in Table 1 for the entire cohort, while the breakdown by every specific study is presented in the Supplementary on-line Appendix (Table S1).

During the follow up, 2244 of 6580 patients (34.1%) had detection of a daily AF burden of at least 5 minutes. In the competing risk analysis, the cumulative incidence of a daily AF burden  $\geq 5$  minutes at 36 months was 40.4% (95%CI: 38.9-41.9%, Figure 1), similarly to the finding of the Kaplan-Meier approach (Figure S1 in the Supplementary Appendix).

The patients with device-detection of AF during follow-up differed from those without AF in terms of a slightly higher age and a slightly higher prevalence of male gender, as well as a lower prevalence of diabetes (Table 1). As shown in Table S2

(Supplementary Appendix), only age  $\geq 75$  years was an independent predictor of new AF in the cohort (HR 1.32, 95%CI: 1.20-1.45,  $p < 0.001$ ).

As shown in Figure 2, in more than half of the cases the first detected AF burden was of limited duration (between 5 min and less than 1 hour) and in about one-fourth of patients it was between 1 and 6 hours. First device detected AF episodes exceeding 6 hours occurred in less than 20% of patients.

### **Transition to a higher device-detected AF burden during follow up**

The transition to a higher daily AF burden over time was assessed in the 2189 patients available for the transition analysis (Figure S2 in the Supplementary Appendix). This group included the patients with a device-detected AF burden of at least 5 minutes after exclusion of 27 patients with a first AF burden of at least 23 hours and 28 patients with the first AF episode occurring on the last day of follow up. One thousand and ninety-one patients (49.8%) had at least one transition from a lower to a higher category of daily AF burden during follow-up. The proportion of patients who had a transition to a higher daily burden on the day immediately following their first-detected AF burden was 17.5% of the whole group (382/2189) and 35.0% (382/1091) of those with a transition from a lower to a higher AF burden (Figure 3, Panel A). Overall the cumulative incidence of transition to a higher device-detected daily AF burden, as estimated in the competitive risk analysis, was 57.5% (95%CI: 54.8-60.1%) at 36 months and 41.0% (95%CI: 38.8-43.1%) in the first 6 months. Similar results were found using the Kaplan Meier approach. (Figure S3 in the Supplementary Appendix).

As shown in Table 2, multivariable analysis indicated that male gender and a CHADS<sub>2</sub> score  $\geq 2$  were significant independent predictors of a transition to a higher AF burden following a first device-detected AF event with a daily AF burden of at least 5 min (HR 1.21, 95%CI: 1.06-1.39,  $p = 0.006$  and HR 1.22, 95%CI: 1.08-1.37,  $p = 0.002$ , respectively). In this analysis the variables that were components of CHADS<sub>2</sub> score were not included in the model, taking into account collinearity. Another model, that instead excluded CHADS<sub>2</sub> score from the analysis, found that male gender, age  $\geq 75$  and hypertension were significant independent predictors of transition to a higher AF burden (Table S3 in the Supplementary Appendix).

The time course and incidence of transition to higher AF burden thresholds is shown in Table 3 for every category of AF burden at first detection. As shown, transition to higher AF burdens was common and a higher threshold of daily AF burden at first detection was associated with a faster transition to a subsequent higher burden. For patients with new AF having a first detection in the category between 5 min and less than 1 hour, the transition to upper thresholds occurred after a median time of 1.5-7.0 months. In contrast, the average time of transition decreased when upper AF burden categories were analyzed, becoming less than 1 month, on average, for the category of AF burden at first detection from 6 hours to <12 hours, and even shorter for the highest categories of AF burden.

The transition to a higher threshold of AF burden occurred in variable proportions on the day after the first device-detected AF burden. Furthermore, these early transitions were more common when the first AF event was in a high category of first-detected daily AF burden.

In Figures S4-S7 (Supplementary Appendix), the time to transition to specific thresholds of higher AF burden is shown for every specific category of AF burden at first detection.

In the same cohort of 2189 patients, 520 subjects (23.8%) experienced a transition of daily AF burden from a lower threshold to a daily AF burden of at least 23 hours. The proportion of patients who had a transition to a burden of at least 23 hours on the day immediately following their first-detected AF burden was 8.6% of the whole group (188/2189) and 36.2% (188/520) of those with a transition from a lower burden to a burden of at least 23 hours. Overall, the probability of transition from a lower AF burden to a daily AF burden of at least 23 hours was 29.6% (95%CI: 27.0 – 32.2% ) at 36 months (Figure 3, panel B) according to the competing risk analysis. Similar results were found using the Kaplan Meier approach (Figure S8 in the Supplementary Appendix).

The incidence and time course of transition from a lower device-detected daily AF burden to a daily AF burden  $\geq 23$  hours differed at the competing risk analysis



according to the category of first device-detected AF burden (Figure 4). The results using the Kaplan Meier approach are shown in Figure S9. As shown in Table 3, 10.1% of patients with an initial AF burden from 5 min to < 1 hour had a transition to a burden  $\geq 23$  hours (in 0.8% occurring the day following the first detection), 24.5% of patients with an initial AF burden from 1 hour to < 6 hours had a transition to a burden  $\geq 23$  hours (in 5.3% occurring the day following the first detection), 49% of patients with an initial AF burden from 6 hours to < 12 hours had a transition to a burden  $\geq 23$  hours (in 20.9% occurring the day following the first detection), and 70.8% of patients with an initial AF burden from 12 hours to < 23 hours had a transition to a burden  $\geq 23$  hours (in 49% occurring the day following the first detection).

As shown in Table 4, multivariable analysis indicated that male gender and a CHADS<sub>2</sub> score  $\geq 2$  were significant independent predictors of transition to an AF burden  $\geq 23$  hours among patients with a first device detected AF with an AF burden of at least 5 min and < 23 hours (HR 1.77, 95%CI: 1.41-2.21  $p < 0.001$ , and HR 1.44, 95% CI: 1.20-1.72,  $p < 0.001$ , respectively). In this analysis the variables that were components of CHADS<sub>2</sub> score were not included in the model, taking into account collinearity. Another model, that alternatively excluded CHADS<sub>2</sub> score from the analysis, found that male gender and age  $\geq 75$  were significant independent predictors of transition to an AF burden  $\geq 23$  hours (Table S4 in the Supplementary Appendix).

## **Discussion**

The present study shows that in patients implanted with a CIED and no clinical history of AF, device-detected atrial tachyarrhythmias, often reported as atrial high rate episodes or subclinical AF, are common, occurring in more than one-third of patients over a period of  $2.4 \pm 1.7$  years. Our study also shows that, in patients with no clinical history of previous AF, the first occurrence of device-detected tachyarrhythmias is usually an AF burden of short duration, from 5 minutes to few hours. Age was the only significant predictor of detection of new AF (with at least 5 minutes of AF burden). It is noteworthy that CHADS<sub>2</sub>, while predicting new AF in univariate analysis, did not independently predict new AF at the multivariable analysis.

Our study identifies several predictors of transition to a higher device-detected AF burden, more relevantly to an AF burden of at least 23 hours. Male gender and CHADS<sub>2</sub> score (or, alternatively, age  $\geq$  75 years in another model) were independent predictors of transition from a lower AF burden to an AF burden  $\geq$ 23 hours. In the literature, different durations of AF burden have been found to be associated with an increased risk of stroke<sup>7,8,18-21</sup> but the threshold at which it is appropriate to initiate OAC in patients at risk is poorly understood and is not defined. Two randomized trials are currently exploring the potential benefits of non-vitamin K antagonists in subclinical AF<sup>13,14</sup>. In the meantime, it appears that the risk of stroke is markedly increased when the duration of the longest episode of AF is more than 24 hours as shown by the recent analysis of ASSERT data<sup>15</sup>, in agreement with previous findings<sup>19</sup>.

The findings of the present study provide further elements for clinical judgment in individual cases. A higher threshold of daily AF burden at first detection was associated with faster transition to a subsequent higher category. Moreover, patients with higher CHADS<sub>2</sub> scores (2-6 vs. 0-1) experienced a faster transition to a higher AF burden category. In patients with a first device-detected AF burden of at least 6 hours, the median time for transition to an AF burden  $\geq$ 23 hours was less than 1 month.

This information could guide recommendations for the frequency of monitoring or the frequency of device interrogations for patients presenting with CIED detected AHREs, in order to make appropriate considerations for oral anticoagulation. Through remote monitoring, physicians could be promptly notified of attainment of specific pre-defined thresholds of AF burden, according to physician's choice, on the basis of individual patient considerations. An individualized approach to device-detected AF could thus be considered by integrating baseline risk factors for stroke with timely quantification of AF burden.<sup>11</sup>

Our observation that patients with a first device-detected AF burden of at least 6 hours have a faster transition to  $\geq$  23hour AF burden may warrant more intensive monitoring in this select group of patients, thereby differentiating this subgroup of patients from those with a lower first device-detected AF burden.

In our study we analyzed device-detected daily AF burden similarly to previous studies that estimated the risk of stroke associated with maximum daily AF burden<sup>8,11,12</sup>. In other studies, the duration of individual AF episodes was analyzed, but this requires careful analysis of every episode in order to correct the consequences of transient phases of under-sensing of the atrial channel that can minimally affect AF burden, but may result in substantial changes in the estimate of individual AF episode duration.<sup>22-24</sup>

A careful review of each stored atrial electrogram for AHRE episodes lasting many minutes to hours is not sustainable in daily practice due to limitations of device storage capability and dedicated personnel. Therefore in order to mimic what happens in daily practice, we considered only the measure of AF burden reported by device diagnostics, the accuracy of which has been previously validated.<sup>23</sup> Of course, as a consequence of using simple device diagnostics for measuring AF burden, a single episode of atrial tachyarrhythmia straddling midnight may be split into AF burden recorded on two consecutive days<sup>8,11,12</sup>.

The assessment of each specific daily burden category and of its transition to subsequent higher categories allows the use of a strictly device-specific analysis of atrial tachyarrhythmias. Our study shows that the burdens of device-detected atrial tachyarrhythmias are not homogeneous with transitions from lower to higher AF burden categories depending on the AF burden at first detection, gender, and CHADS<sub>2</sub> score. Currently clinical decision making regarding the need for anticoagulation remains uncertain, but if the profile is known to be at risk (CHADS<sub>2</sub> score  $\geq 2$ ) considerations of the probability of transition to an AF burden  $\geq 23$  hours can offer further elements to take into account.<sup>15,19</sup>

Our study has some limitations, reported in the Supplementary web-only Appendix.

## **Conclusions**

Patients implanted with a pacemaker, ICD, or CRT device and no previous clinical history of AF, have episodes of device detected atrial tachyarrhythmias  $\geq 5$  min frequently, occurring in around one-third of patients at 2 years of follow up and age is an independent predictor. These device-detected atrial tachyarrhythmias can be

classified in categories of daily AF burden. The transition from lower to higher AF burden categories depends on the AF burden at first detection, and CHADS<sub>2</sub> score. The longer the duration of AF burden, the higher the probability of a faster transition to a AF burden  $\geq 23$  hours, a threshold that is associated with an increase in the risk of stroke. The independent predictors of transition from a lower to a higher AF burden are male gender, and CHADS<sub>2</sub> score and this may help in individualizing monitoring and clinical surveillance. Continuous long-term EKG monitoring, by capturing transitions to higher AF burden thresholds could support timely anticoagulation decisions in patients with increased risk of stroke and no history of AF.

### **Acknowledgments**

The authors thank Andrea Grammatico, PhD for useful suggestions and assistance during manuscript preparation.

### **References**

1. Healey JS, Connolly SJ, Gold MR, et al. Subclinical Atrial Fibrillation and the Risk of Stroke. *N Engl J Med.* 2012;366:120-129.
2. Gorenek B, Pelliccia A, Benjamin EJ, et al. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHS). *Europace.* 2017;19:190-225.
3. Freedman B, Boriani G, Glotzer TV, Healey JS, Kirchhof P, Potpara TS. Management of atrial high rate episodes detected by cardiac implanted electronic devices. *Nat Rev Cardiol.* 2017 Jul 6. doi: 10.1038/nrcardio.2017.94. [Epub ahead of print].
4. Charitos EI, Pürerfellner H, Glotzer TV, Ziegler PD. Clinical classifications of atrial fibrillation poorly reflect its temporal persistence: Insights from 1,195 patients continuously monitored with implantable devices. *J Am Coll Cardiol.* 2014;63:2840-2848.
5. Boriani G, Pettoelli D. Atrial fibrillation burden and atrial fibrillation type: Clinical significance and impact on the risk of stroke and decision making for long-term anticoagulation. *Vascul Pharmacol.* 2016;83:26-35.
6. Boriani G, Valzania C, Biffi M, Diemberger I, Ziacchi M, Martignani. Asymptomatic lone atrial fibrillation-how can we detect the arrhythmia? *Curr Pharm Des.* 2015;21:659-666.
7. Glotzer TV, Daoud EG, Wyse DG, et al. The Relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk the trends study. *Circ Arrhythmia Electrophysiol.* 2009;2:474-480.
8. Boriani G, Glotzer TV, Santini M, et al. Device-detected atrial fibrillation and risk for stroke:

- An analysis of >10 000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). *Eur Heart J*. 2014;35:508-516.
9. Hess PL, Healey JS, Granger CB, et al. The role of cardiovascular implantable electronic devices in the detection and treatment of subclinical atrial fibrillation. *JAMA Cardiol*. 2017;2:324. d
  10. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Europace*. 2016;18:1609-1678.
  11. Botto GL, Padeletti L, Santini M, et al. Presence and duration of atrial fibrillation detected by continuous monitoring: Crucial implications for the risk of thromboembolic events. *J Cardiovasc Electrophysiol*. 2009;20: 241-248.
  12. Boriani G, Botto GL, Padeletti L, et al. Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. *Stroke*. 2011;42:1768-1770.
  13. Healey JS. Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation. [Http://clinicaltrials.gov/show/NCT01938248](http://clinicaltrials.gov/show/NCT01938248). ClinicalTrials.gov. Published 2016.
  14. Kirchhof P. Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes (NOAH). [Http://clinicaltrials.gov/show/NCT02618577](http://clinicaltrials.gov/show/NCT02618577). ClinicalTrials.gov. Published 2016.
  15. Van Gelder IC, Healey JS, Crijns HJGM, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. *Eur Heart J*. 2017;38:1339-1344.
  16. Kirchhof P, Blank B, Calvert M, Camm A. Probing oral anticoagulation in patients with atrial high rate episodes. Rationale and design of the Non vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.. *Am Hear*. 2017;190:12-18.
  17. Lamas G. How much atrial fibrillation is too much atrial fibrillation? *N Engl J Med*. 2012;366:178-180.
  18. Glotzer TV, Hellkamp AS, Zimmerman J, et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: Report of the atrial diagnostics ancillary study of the MOde Selection Trial (MOST). *Circulation*. 2003;107:1614-1619.
  19. Capucci A, Santini M, Padeletti L, et al. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. *J Am Coll Cardiol*. 2005;46:1913-1920.
  20. Boriani G, Padeletti L. Management of atrial fibrillation in bradyarrhythmias. *Nat Rev Cardiol*. 2015;12:337-349.
  21. Freedman B, Camm J, Calkins H, et al. Screening for Atrial Fibrillation. *Circulation*. 2017;135:1851-1867. 3.
  22. Pollak WM, Simmons JD, Interian A, et al. Clinical utility of intraatrial pacemaker stored electrograms to diagnose atrial fibrillation and flutter. *Pacing Clin Electrophysiol*. 2001;24:424-429.
  23. Purefeller H, Gillis AM, Holbrook R, Hettick DA. Accuracy of atrial tachyarrhythmia detection in implantable devices with arrhythmia therapies. *PACE - Pacing Clin Electrophysiol*. 2004;27:983-992.
  24. Passman RS, Weinberg KM, Freher M, et al. Accuracy of mode switch algorithms for detection of atrial tachyarrhythmias. *J Cardiovasc Electrophysiol*. 2004;15:773-777.

## Tables

**Table 1.** Clinical characteristics of the cohort and of patients with and without AF detected during follow up.

	<b>Total (n=6580)</b>	<b>No AF Detected (n=4336)</b>	<b>AF Detected (n=2244)</b>	<b>p-value</b>
<b>Baseline and Demographic Characteristics</b>				
<b>Age (years), mean <math>\pm</math> SD</b>	67 $\pm$ 12	67 $\pm$ 12	68 $\pm$ 12	<0.001
<b>Male, n (%)</b>	4569 (69.5%)	2958 (68.3%)	1611 (71.9%)	0.003
<b>Diabetes, n (%)</b>	1734 (28.3%)	1188 (29.2%)	546 (26.4%)	0.019
<b>Hypertension, n (%)</b>	3754 (61.6%)	2527 (62.5%)	1227 (60.0%)	0.060
<b>Heart failure, n (%)</b>	6465 (56.6%)	2399 (56.3%)	1257 (57.0%)	0.615
<b>CHADS <math>\geq</math> 2, n (%)</b>	3735 (56.8%)	2475 (57.1%)	1260 (56.1%)	0.470
<b>Prior stroke, n (%)</b>	293 (4.7%)	207 (5.0%)	86 (4.1%)	0.125
<b>Implanted device</b>				
<b>Pacemaker, n (%)</b>	2555 (38.8%)	1672 (38.6%)	883 (39.3%)	0.100
<b>ICD, n (%)</b>	1401 (21.3%)	960 (22.1%)	441 (19.7%)	
<b>CRT, n (%)</b>	2586 (39.3%)	1677 (38.7%)	909 (40.5%)	

**Table 2.** Predictors of transition to a higher AF burden following first device-detected AF with an AF burden of at least 5 min (excluding from the multivariable analysis the individual components of CHADS<sub>2</sub> score).

Parameter	Univariate		Multivariate	
	HR (95%CI)	p-value	HR (95%CI)	p-value
Male Gender*	<b>1.22 ( 1.06 - 1.40)</b>	<b>0.006</b>	1.21 (1.06-1.39)	0.006
Age ≥ 75	<b>1.18 ( 1.04 - 1.34)</b>	<b>0.009</b>		
Diabetes	1.08 ( 0.94 - 1.24)	0.281		
Prior Stroke	1.00 ( 0.73 - 1.38)	0.982		
Hypertension	<b>1.24 ( 1.09 - 1.41)</b>	<b>0.001</b>		
Heart Failure	1.07 ( 0.95 - 1.21)	0.253		
CHADS <sub>2</sub> ≥ 2*	<b>1.22 ( 1.08 - 1.38)</b>	<b>0.001</b>	1.22 (1.08 - 1.37)	0.002
CRT	1.04 ( 0.92 - 1.17)	0.514		

\*Included in the stepwise multivariable method.

**Table 3.** Transition to a specific category of higher device-detected daily AF burden for patients presenting specific categories of AF burden at first detection.

<b>Patients (N= 1165) with first AF burden from 5 Minutes to &lt; 1hour.</b>					
	Patients with transition (%)	Median time of transition, months (95% CI)	Patients of this AF burden subgroup with transition occurring the day after the first device-detected AF burden (%)	6-Months Incidence of transition to a higher AF burden (95% CI)	36-Months Incidence of transition to a higher AF burden (95% CI)
Transition to an AF burden $\geq$ 1 hour	497 (42.7%)	1.4 (0.1-6)	96 (8.2%)	33.5% (30.7-36.3%)	50.5% (46.8-54.1%)
Transition to an AF burden $\geq$ 6 hours	267 (22.9%)	3.1 (0.3-10.6)	35 (3%)	15.3% (13.2-17.5%)	29.9% (26.4-33.5%)
Transition to an AF burden $\geq$ 12 hours	178 (15.3%)	3.8 (0.4-13.4)	20 (1.7%)	8.9% (7.3-10.7%)	21.3% (18.0-24.7%)
Transition to an AF burden $\geq$ 23 hours	118 (10.1%)	6.9 (0.8-14.9)	9 (0.8%)	5.1% (3.9-6.5%)	14.5% (11.7-17.6%)

<b>Patients (N= 588 ) with first AF burden from 1 hour to &lt;6 hours</b>					
	Patients with transition (%)	Median time of transition, months (95% CI)	Patients of this AF burden subgroup with transition occurring the day after the first device-detected AF burden (%)	6-Months Incidence of transition to a higher AF burden (95% CI)	36-Months Incidence of transition to a higher AF burden (95% CI)
Transition to an AF burden $\geq$ 6 hours	307 (52.2%)	0.6 (0.1-4.3)	103 (17.5%)	42.2% (38.1-46.3%)	61.8% (56.2-66.9%)
Transition to an AF burden $\geq$ 12 hours	222 (37.8%)	1.2 (0.1-9.5)	68 (11.6%)	27.5% (23.9-31.3%)	45.3% (39.9-50.6%)
Transition to an AF burden $\geq$ 23 hours	144 (24.5%)	2.9 (0.1-14.7)	31 (5.3%)	16.0% (13.1-19.2%)	29.6% (26.7-34.6%)



<b>Patients (N= 234 ) with first AF burden from 6 hours to &lt;12 hours</b>					
	Patients with transition (%)	Median time of transition, months (95% CI)	Patients of this AF burden subgroup with transition occurring the day after the first device-detected AF burden (%)	6-Months Incidence of transition to a higher AF burden (95% CI)	36-Months Incidence of transition to a higher AF burden (95% CI)
Transition to an AF burden $\geq$ 12 hours	144 (61.5%)	0.03 (0.03-2)	84 (35.9%)	55.8% (49.1-62.0%)	65.1% (57.5-71.7%)
Transition to an AF burden $\geq$ 23 hours	115 (49.1%)	0.07 (0.03-2.6)	49 (20.9%)	40.6% (34.2-46.8%)	56.4% (47.9-64.0%)

<b>Patients (N= 202 ) with first AF burden from 12 hours to &lt;23 hours</b>					
	Patients with transition (%)	Median time of transition, months (95% CI)	Patients of this AF burden subgroup with transition occurring the day after the first device-detected AF burden (%)	6-Months Incidence of transition to a higher AF burden (95% CI)	36-Months Incidence of transition to a higher AF burden (95% CI)
Transition to an AF burden $\geq$ 23 hours	143 (70.8%)	0.03 (0.03-0.16)	99 (49%)	63.1% (56.0-69.4%)	78.2% (67.0-86.0%)

**Table 4.** Predictors of transition to a AF burden  $\geq 23$  hours following first device detected AF with a AF burden of at least 5 min (excluding from the multivariable analysis the individual components of CHADS<sub>2</sub> score).

Parameter	Univariate		Multivariate	
	HR (95%CI)	p-value	HR (95%CI)	p-value
Male Gender *	<b>1.78 ( 1.42 - 2.22)</b>	<b>&lt;0.001</b>	1.77 (1.41 - 2.21)	<0.001
Age $\geq 75$	<b>1.32 ( 1.10 - 1.58)</b>	<b>0.003</b>		
Diabetes	1.09 ( 0.88 - 1.33)	0.430		
Prior Stroke	1.13 ( 0.73 - 1.75)	0.586		
Hypertension	<b>1.26 ( 1.04 - 1.52)</b>	<b>0.017</b>		
Heart Failure	<b>1.19 ( 0.99 - 1.42)</b>	<b>0.060</b>		
CHADS <sub>2</sub> $\geq 2$ *	<b>1.45 ( 1.21 - 1.73)</b>	<b>&lt;0.001</b>	1.44 (1.20 - 1.72)	<0.001
CRT	<b>1.26 ( 1.06 - 1.50)</b>	<b>0.008</b>		

\*Included in the stepwise multivariable method

**Figure legends**


**Figure 1.** Incidence of first device-detected AF, considered as daily AF burden  $\geq 5$  min, taking into account the competing risk of death.

**Figure 2.** Distribution of AF daily burden for first device-detected AF.


**Figure 3, panel A.** Incidence of transition from a lower to a higher category of daily AF burden in patients with a first device detected AF burden of at least 5 min, taking into account the competing risk of death.

**Figure 3, panel B.** Incidence of transition from a lower daily AF burden to a daily AF burden  $\geq 23$  hours in patients with a first device detected AF of at least 5 min, taking into account the competing risk of death.


**Figure 4.** Incidence of transition to AF burden  $\geq 23$  hours for patients characterized by different AF burden categories at first AF detection, taking into account the competing risk of death.




**Figure 1.** Incidence of first device-detected AF, considered as daily AF burden  $\geq 5$  min, taking into account the competing risk of death.




**Figure 2.** Distribution of AF daily burden for first device-detected AF.



**Figure 3. panel A.** Incidence of transition from a lower to a higher category of daily AF burden in patients with a first device detected AF burden of at least 5 min, taking into account the competing risk of death.





**Figure 3, panel B.** Incidence of transition from a lower daily AF burden to a daily AF burden  $\geq 23$  hours in patients with a first device detected AF of at least 5 min, taking into account the competing risk of death.





**Figure 4.** Incidence of transition to AF burden  $\geq 23$  hours for patients characterized by different AF burden categories at first AF detection, taking into account the competing risk of death.














ACCEPTTEL